Column Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Column Capital Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$6.58K	Hold	145	–	–	﹤0.01%	571
2023 Q2	$8.14K	Hold	145	–	–	﹤0.01%	562
2023 Q1	$6.56K	Hold	145	–	–	﹤0.01%	610
2022 Q4	$5.89K	Hold	145	–	–	﹤0.01%	597
2022 Q3	$9K	Hold	145	–	–	﹤0.01%	479
2022 Q2	$9K	Hold	145	–	–	﹤0.01%	489
2022 Q1	$9K	Hold	145	–	–	﹤0.01%	512
2021 Q4	$11K	Buy	145 +58	+67%	+$5.07K	﹤0.01%	496
2021 Q3	$10K	Hold	87	–	–	﹤0.01%	465
2021 Q2	$14K	Buy	87 +45	+107%	+$5.47K	﹤0.01%	425
2021 Q1	$5K	Buy	+42	New	+$6.34K	﹤0.01%	532
2020 Q1	–	Sell	-61	Closed	-$3K	–	735
2019 Q4	$3K	Buy	+61	New	+$3.33K	﹤0.01%	568

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Column Capital Advisors's CRSP Position: Q3 2023 in Review

Column Capital Advisors held its CRISPR Therapeutics (CRSP) position steady in Q3 2023 at 145 shares worth $6.58K. The position accounts for ﹤0.01% of the portfolio, ranked #571.

Column Capital Advisors first reported a position in CRSP in Q4 2019 and has held it in 12 quarters since. The position peaked at $14K in Q2 2021. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

Column Capital Advisors held 145 shares of CRISPR Therapeutics worth $6.58K as of Q3 2023.
Column Capital Advisors left its CRISPR Therapeutics share count unchanged in Q3 2023.
CRISPR Therapeutics made up ﹤0.01% of Column Capital Advisors's portfolio in Q3 2023, its #571 holding.
Column Capital Advisors first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 12 quarters since.
Column Capital Advisors's CRISPR Therapeutics position peaked at $14K in Q2 2021.
406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.